Similar preclinical findings have also been reported for the pure anti-ER fulvestrant [10], and recent clinical studies examining cotargeting ER and EGFR and/or ErbB2 signalling pathways have reported improved response to a range of endocrine therapies in breast cancer patients [20,21]. Here, ERBB2 is linked to breast cancer.